Dr. Hongjun Wang has completed her PhD from China Agricultural University and postdoctoral studies at the University of Rome, “La Sapienza” and St. Jude Children’s Hospital. She was an instructor and Assistant Professor at the Harvard Medical School/Beth Israel Deaconess Medical Center from 2001-2011. She is now a full Professor and the Scientific Director of the Center for Cellular Therapy, at the Medical Univeristy of South Carolina, USA. Dr. Wang has published more than 50 papers in reputed journals and has been serving as an editorial board member of repute.

His research interest includes Cell Therapy, Stem cell, surgery, Gene therapy

SIMONE PACINI has completed his PhD in 1997. Until 2003 he was active in oncohematology and responsible of flow cytometry and cell sorting facility. Later, his studies focused on clinical use of MSCs and participated actively on isolation of a novel progenitor of MSC in adult human bone marrow. He is currently working in collaboration reputed Universities and Medical Colleges. Actaually, he is lab director of the “Michele Cavaliere Laboratories for Cell Therapy ” at University of Pisa. He has published more than 40 papers in reputed journals and he is editorial board member of the Frontiers in Cell Developmental Biology journal.

His research interests includes cell therapy, cell development, oncohematology, cell sorting.

Jehad Zweiri, lecturer in Cancer studies at the University of Liverpool Medical School, born and grew up in Jordan and received his Bachelor’s degree from the University of Jordan in 1990. He obtained his master degree from London School of Hygiene and Tropical Medicine/University of London, and then obtained his PhD degree in 2000 from Kings College Medical School/University of London, in the field of Immune Gene Therapy of Cancer under the supervision of Professor Farzin Farzaneh. He then started his work as Postdoctoral Associate at the department of Immunology and Medicine at the University of Liverpool in 2002. In 2010 he was appointed as a lecturer in the university of Liverpool medical school and he is currently fellow of the British Higher Education Academy since 2012.

His research interests include Gene Therapy, Cancer Studies, Immunology, Medicine

Sergey Suchkov received his MD from Astrakhan State Medical University. In 1985, he received his PhD from the I M Sechenov Moscow Medical Academy and in 2001, his Doctorship Degree at the Nat Institute of Immunology, Russia. From 1987 through 1989, he was a Senior Researcher, Koltzov Institute of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, he was the Chair of the Department of Clinical Immunology, Moscow Clinical Research Institute. He was an Exe Secretary-in-Chief of the Editorial Board of Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is a Chair at the Department for Personalized and Translational Medicine, I M Sechenov First Moscow State Medical University. He is a Member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research) and PMC (Personalized Medicine Coalition), Washington, USA.

Translational Medicine

Dr. Dayong Gao is a Professor of Mechanical Engineering and Adjunct Professor of Bioengineering at the University of Washington College of Engineering, Seattle, WA. He is an academician of Washington State Academy of Sciences. Prior to joining the University of Washington, he was a Professor of Mechanical Engineering and Biomedical Engineering at the University of Kentucky, where he was elected and honored as Endowed Alumni Professor and Baxter Healthcare Corp Chair in Engineering. Dr. Gao’s work has been recognized and supported through numerous awards and grants from research funding agencies, including National Institutes of Health (NIH), Department of Defense, National Science Foundation, National Cancer Society, American Heart Association, Bill and Melinda Gates Foundation, Whitaker Foundation, Washington Research Foundation, and many industries. Supported by major grants from the Bill & Melinda Gates Foundation and NIH, he currently serves as the Director and PI of an international consortium to investigate and develop optimal conditions and technology for cryopreservation of human mucosal immune cells and tissues for HIV vaccine and new drug/microbicide development and assessment.

Fundamental and applied cryobiology: revealing the mechanisms of cryoinjury to living biological systems at low temperatures, development of optimal methods, novel technology and instruments for long-term cryopreservation/banking of living cells, tissues and organs for cellular and gene therapy, tissue engineering, regenerative medicine and organ transplantation; Development of a new generation of artificial organs, especially artificial kidney and liver systems for treatment of end-stage kidney and liver failure; Bio-instruments and micro/nano-sensors (BioMEMS) for rapid and cost-effective diagnosis of diseases with high sensitivity and specificity.

James K.Williams have been at Wake Forest University for 30 years. During that time, his research focus has been women’s health. While now a faculty member of Regenerative Medicine, his past research focused on the use of animal models to explore the effects of aging and sex hormones on the cardiovascular and urogenital systems. When moving to the Wake Forest Institute for Regenerative Medicine (WFIRM), his focus remained on women’s health and was funded for 4 years and now funded for an additional 4 years to explore the utility of cell therapy for urinary incontinence – using nonhuman primates as the animal model.

Cell Therapy,Estrogen Replacement Therapy,Ovariectomy

Professor Dr. Luisa Maria Arvide Cambra, Spanish is now Professor with Chair at the University of Almería (Spain). She also taught at the University of Granada, Spain. Thirty four years of teaching and researching experience. She is Director of Research Group HUM113-Estudios Filológicos from Program of Research of Andalusian Government, where she has managed and directed several academic and scientific contracts and research projects.She is author of a many works on several aspects of the Arabic science and literature in the Middle Ages, as well as Arabic language and linguistics. She has also participated in different prestigious international scientific conferences and visited many Universities and academic institutions in Europe, United States and Arab countries to teach and research.

Philological studies,Humanities

Dr. Yang is an Associate Professor in Department of Anatomy & Cell Biology, University of Pennsylvania, School of Dental Medicine. She received her MD (1994) and PhD (2000) in China. She then completed postdoctoral fellowships in bone biology at The Forsyth Institute & Harvard School of Dental Medicine and the University of Michigan School of Dentistry. She was appointed an assistant Professor in Department of Oral Biology, in State University of New York at Buffalo in 2008 and then became a tenured associate professor in 2014, She joined University of Pennsylvania in June 2016. She is an author of over 50 papers published in international journals including Nature Communication, Cell Death & Differentiation, Journal of Bone & Mineral Research, Human Molecular Genetics, a reviewer for numerous journals and editorial board of several journals. She and her lab members are the recipients of numerous research awards including Most outstanding abstract award for top one abstract in American Society of Bone and Mineral Research Annual Meeting, ASBMR-John Haddad Young investigator award, Young Investigator Award. Dr. Yang’s lab has pursued innovative research on the mechanisms of bone formation and resorption, including craniofacial and bone development, metabolism and mechanostransduction, and stem cell-mediated bone regeneration.

Craniofacial and bone development, bone remodeling and mechanotransduction, stem cell and gene therapy mediated bone repair and regeneration.

A Yilmazer is working as an Assistant Professor in the Biomedical Engineering Department of Ankara University. She has been the Vice Director of the Stem Cell Institute of Ankara University since December 2016. She completed her MSc degree in Cancer Immunotherapy from the University of Nottingham (UK) and obtained her PhD in the Nanomedicine Lab based in the School of Pharmacy, University College London. She has published papers on nanomedicine, cancer therapy and cellular reprogramming in various distinguished journals

Cell Therapy, Gene Therapy, Nano Medicine, cancer therapy and cellular reprogramming.

Nayef Jarrous is currently working at The Hebrew University of Jerusalem, Israel. His research interest is based on Human nuclear RNase P ribonucleoprotein in tRNA processing. He has published many articles in reputed journals.

Human nuclear RNase P ribonucleoprotein in tRNA processing and transcription

Dr. Brij. M. Gandhi is the Chief Executive Officer and founder of Neo BioMed Services (www.neobiomed.com), a company which provides services and consultancy in health related areas. The Company with a branch office in Cleveland, UK (www.neobiomed.co.uk) serves as the focal point for providing services and solutions to the healthcare community in Europe. His basic skills and experiences is in areas of Management; Research and Development; Policy and Strategic Planning; Market Strategy; Technology Transfer; Sales; Biodefence Strategies; Institutional Development and Regulatory Issues related to biopharmaceuticals, pharmaceuticals, herbals and food safety, biosafety and biosecurity and healthcare areas including stem cell and regenerative medicine. Dr. Gandhi retired in 2006 as Adviser to the Government of India, Ministry of Science and Technology, Department of Biotechnology, after serving for over 18 years in various capacities managing promotion and policy related issues in biotechnology related to international collaborations, medical biotechnology, infrastructure development, animals and aquaculture biotechnology. Prior to that Dr. Gandhi had been a Research Scientist at the All India Institute of Medical Sciences, New Delhi for about twenty years. Dr. Gandhi continues to serve as Advisor / Director to a number of institutions/pharma and biopharma industries including MNCs and has an experience of over 49 years of active service, as research scientist, science manager, adviser/consultant with over 155 publications. Dr.Gandhi also as Director of a Mumbai based Stem Cell Company has been involved in medical practice for regenerative medicine. Dr. Gandhi had his Masters in Biochemistry from PAU and Ph.D. in Experimental Medicine from the University of Bergan, Norway. He was trained at the Massachusetts Institute of Technology, USA; London School of Hygiene and Tropical Medicine, London; National Institutes of Health, Maryland, USA; and University of Bergan, Norway.

Immunology and diagnostics for parasitic, bacterial and viral infections especially amoebic diseases; viral diseases including hepatitis viruses; liver diseases; stem cells and regenerative medicine; food and nutritional health issues.

Decio Basso has earned his Medical degree in 1982 from the Federal University Santa Catarina (UFSC), at Florianopolis, Brazil. He then attended PUC-Pontifical Catholic University of Rio Grande do Sul, Brazil to pursue a specialization Medical Degree Geriatric and Gerontology in 1990; after graduating, he was for an internship continuing education at Harvard Medical School in Boston, USA. He has been an integral part of medical staff at The Department of Immunology at the University of British Columbia, Canada. He is serving as a Professor at UPE (Universidad Privada Del Este, Paraguay). He is the Founder of the Gerobasso Medical Research Center; a medical research organization.

Stem Cells

Jonathan Schwartz has over 30 years doing international business consulting for emerging medical technologies and has been focused on stem cell technologies and regenerative medicine for the past six years. He currently is the Managing Director of the Regenerative Cellular Institute in the United States and does business consulting for several companies globally, including, Mystem, Bioquark, WinCell, StemCells21, IntellihealthPlus, Al Mediq, Glo PRP, WeHealPlus, and Arpwave. He has previously worked in many capacities with Spacelabs Medical, GE Healthcare, Intellicell Biosciences, Coloplast, and Smith and Nephew. He has degrees from Queens College, Almeda University and NYU Medical School.

His research interests are stem cells, regenerative medicine, cell therapy. clinical trails.

Pedro Morouço is the Head of R&D Biofabrication Group at the Centre for Rapid and Sustainable Product Development – Polytechnic Institute of Leiria, Portugal, with a PhD specialized in Biomechanics. His research activity focuses, mostly, on products and processes engineering, aiming to bringing the gap between the lab and in vivo applications. He has Co-edited 3 books, authored and co-authored more than 100 papers published in book-chapters (n=15), international journals (n=40) and international conferences (n=55). He is Editorial Board Member in several international peer-review journals and was distinguished with the New Investigator Award 2014 from ISBS. He coordinates granted national and international research projects and is the Chairman of the CDRsp Advanced Courses on Regenerative Medicine and Workshops on Direct Digital Manufacturing for Medicine.

His research interests are Biomechanics, stem cell and regenerative medicine.

Taihua Wang has completed his MD in 1983 from Shandong Medical University and obtained his Postdoctoral studies in Danish Royal Hospital from 1990 to 1993. He is the Director of Interventional Hospital of Shandong Red Cross Society, one of the top hospitals in China. He has published more than 20 papers in reputed journals and was awarded 7 national patents. He is pioneer of stem cell therapy in the world and has extensive collaborations with Harvard Medical School, University of Pennsylvania, etc. He has already performed several thousand clinical cases with stem cells during the past 12 years.

clinical cases with stem cells

Decio Basso has earned his Medical degree in 1982 from the Federal University Santa Catarina (UFSC), at Florianopolis, Brazil. He then attended PUC-Pontifical Catholic University of Rio Grande do Sul, Brazil to pursue a specialization Medical Degree Geriatric and Gerontology in 1990; after graduating, he was for an internship continuing education at Harvard Medical School in Boston, USA. He has been an integral part of medical staff at The Department of Immunology at the University of British Columbia, Canada. He is serving as a Professor at UPE (Universidad Privada Del Este, Paraguay). He is the Founder of the Gerobasso Medical Research Center; a medical research organization.

Immunology, gene therapy, cell therapy

Guillermo Estivill Torrús completed his PhD from University of Málaga (Spain) and postdoctoral studies from University of Edinburgh Medical School (UK). From 2002 he is the leader of the research group CTS643 “Applied Neuropsychopharmacology for Neurological and Neuropsychiatric diseases”. He is also Co-Principal Researcher of the research group "Neuroimmunology-Multiple Sclerosis" in the IBIMA, and Manager of the Image Unit (common support structures for research) in the same institution. More than 30 articles reflect his research concerning mostly the role of regulatory lipid molecules, mainly lysophosphatidic acid, on the central nervous system.

Neuroscience, Neurology

Mr. Deven Patel, the CEO, President and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A. GIOSTAR was formed with the vision to provide affordable stem cell based therapies to the masses around the world suffering from degenerative or genetic diseases and unable to afford today’s high cost of the treatment.

Stem cell, Regenerative Medicine

She is head of the Pathology Department in the Fundació Institut de Recerca Hospital which is located in Spain.

Cancer Research, Genetics, Histology

José Sánchez del Río Sáezhas been working in biotechnology with photonic biosensors for more than 4 years. He did his PhD in photonic bio-sensing and DNA mutations detection at Madrid Microelectronics Institute (IMM-CNM-CSIC). Then he worked in a private company as a patent researcher in Biometrics and novel sensors and after as a postdoc in the Face Recognition and Artificial Vision (FRAV) group of the Computer and Statistics department at Rey Juan Carlos University (URJC). He has done 2 postdocs in the Nuclear Physics Department at the Matter Structure Institute (IEM-CSIC) and was specialized in high energy ions, protons and gamma radiation detection. He was working as a SW/HW testing engineer in the aerospace field for ALTER TECHNOLOGY and now he is an instrument scientist at IMDEA and lecturer of electronics subjects as associated professor at UC3M.

Photonic Biosensors and Radiation detection

Mukesh Verma is Chief of the Epidemiology and Genomics Research Program's (EGRP) Methods and Technologies Branch (MTB), and oversees its research portfolio and initiatives that focus on methods to address epidemiologic data collection, study design and analysis, and to modify technological approaches developed in the context of other research endeavors for use as biomarkers and methods to understand cancer susceptibility. He is responsible for stimulating EGRP-funded research on epigenetic approaches in cancer epidemiology and has been instrumental in developing epigenetics research for NIH as a whole. Dr. Verma helped to develop a Request for Applications (RFA) on Environmental Influences on Epigenetics with the National Institute of Environmental Health Sciences (NIEHS) and represents the Division of Cancer Control and Population Sciences (DCCPS), in NIH's Roadmap Initiative on EpigeneticsExternal Web Site Policy. He helped develop an RFA on Comparative Systems Genetics of Cancer with NCI's Division of Cancer Biology (DCB), and is known within the extramural research community as an EGRP Program Director for Program Announcements (PAs) on Small Grants for Cancer Epidemiology and Pilot Studies in Pancreatic Cancer. He also organized a workshop to explore developing a concept for a research initiative on mitochondrial DNA and cancer epidemiology. Dr. Verma was, and continues to be, a co-Program Director for initiatives in gene-environment interactions in cancer etiology, including the Breast and Prostate Cancer and Hormone-Related Variants Cohort Consortium (BPC3), which is a collaborative project to pool data and biospecimens from a group of large prospective cancer epidemiology cohorts. Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP's former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI's Division of Cancer Prevention (DCP), where he worked in the areas of biomarkers, early detection, risk assessment, and prevention. He also was Coordinator of DCP's Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.

Biomarkers, Epigenetics, Epidemiology Technologies, Proteomics, MicroRNA, Methylation, Mitochondria, Nanotechnology, Risk Assessment, Susceptibility Factors, Systems Genetics, Metabolomics

Brij. M. Gandhi is the Chief Executive Officer and founder of Neo BioMed Services (www.neobiomed.com), a company which provides services and consultancy in health related areas. Dr. Gandhi is also Director of a Mumbai based Stem Cell Company, EmProCell Clinical Research Private Limited, involved in medical practice for regenerative medicine. His basic skills and experiences is in areas of Science Management; Research and Development; Policy and Strategic Planning; Management; Market Strategy; Technology Transfer; Sales and Management; Biodefence Strategies; Institutional Development / regulatory issues related to biopharmaceuticals, pharmaceuticals, biosafety and biosecurity and healthcare areas including stem cell and regenerative medicine. Dr. Gandhi retired in 2006 as Adviser to the Government of India, Ministry of Science and Technology, Department of Biotechnology, after serving for over 18 years in various capacities managing promotion and policy related issues in biotechnology related to international collaborations, medical biotechnology, infrastructure development, animals and aquaculture biotechnology. Prior to that Dr. Gandhi had been a Research Scientist at the All India Institute of Medical Sciences, New Delhi for about twenty years. Dr. Gandhi continues to serve as Advisor / Director to a number of institutions/pharma and biopharma industries including MNCs and has an experience of over 45 years of active service, as research scientist, science manager, adviser/consultant with over 150 publications. Dr. Gandhi had his Masters in Biochemistry from PAU and Ph.D. in Experimental Medicine from the University of Bergan, Norway. He was trained at the Massachusetts Institute of Technology, USA; London School of Hygiene and Tropical Medicine, London; National Institutes of Health, Maryland, USA; and University of Bergan, Norway.

Immunology and diagnostics for parasitic, bacterial and viral infections especially amoebic diseases; viral diseases including hepatitis viruses; liver diseases; stem cells and regenerative medicine; food and nutritional health issues.

J. Sánchez de Río has completed his PhD at the age of 28 years from Autónoma University and he has done his postdoctoral studies at the IEM-CSIC Experimental Nuclear Physics Group. He is now working as a researcher in the Statistics and Informatics department at Rey Juan Carlos University. He has published more than 25 papers in reputed journals and 4 patents related to Biometrics. He has participated in many international conferences related to Environmental Science, Photonics, Nuclear Science and Pattern Recognition. He has been lecturer of Biophysics at IE University.

Environmental Science, Photonics, Nuclear Science and Pattern Recognition

Vasiliki E. Kalodimou MSc, Ph.D is the director of the Flow Cytometry-Research and Regenerative Medicine Department at IASO Hospital in Athens, Greece. She has studied and worked with progenitor cells from placenta, umbilical cord, and adipose tissue along with their applications in regenerative medicine and flow cytometry, with publications in the field, including research fellowships. She has published 2 books about flow cytometry, the Greek edition was published in 2010 and in 2013 the book was published from AABB Press USA. She is a Flow Cytometry Specialist, Associate Leader at AABB CT Subsection: CT Product Manufacturing and Testing, USA, Scientific Consultant in Regenerative Plastic Surgery Institute / Pure Aesthetics, Brazil, AABB Assessor, USA, editor in 3 scientific journals and her biography was included in Who Is Who in the world 2014 & 2015edition.

She has studied and worked with progenitor cells from placenta, umbilical cord, and adipose tissue along with their applications in regenerative medicine and flow cytometry.

Raj Kumar, Ph.D. is a professor of Biochemistry in the Department of Basic Sciences at The Commonwealth Medical College (TCMC), Scranton, PA. Dr. Kumar received his Ph.D. degree from University of Lucknow, India and was a postdoctoral fellow at the University of Texas Medical Branch (UTMB), Galveston, TX. Before moving to TCMC, Dr. Kumar held a position of Associate Professor in the department of Internal Medicine at UTMB, Galveston, TX. He is a basic researcher with a long-standing interest in examining the role of structural dynamics of steroid hormone receptors in gene regulation in physiology and diseases, and has an extensive list of publications in this area in highly reputed peer reviewed journals. Dr. Kumar has trained a number of students and postdoctoral fellows in his laboratory. Dr. Kumar has served as a reviewer for about 40 scientific journals, and several national and international grant review panels.

Structure and functions of transcription factors; Protein Folding & Biophysics; Macromolecular Interactions; Cell Signaling and Gene Regulation; Post translational modifications

Dr. Uday Kishore, a cellular and molecular immunologist, is the Director of the Centre for Infection, Immunity and Disease Mechanisms, Brunel University, London. He researches on the role of innate immunity in a range of disease processes and therapeutic interventions. He earned his MSc and PhD from University of Delhi, India. He has previously been a NASA Fellow at Salk Institute, USA, MRC Fellow at Oxford, and Humboldt Fellow in Germany. He has authored over 100 research papers, 20 book chapters, 2 patents and edited 3 books. He is also the recipient of MRC Inventor’s prize, European Commission Young Scientist prize, and, more recently, Mother Teresa Excellence Award 2014.

cellular and molecular immunology

Dr. Weihua Gong is a Ph.D. mentor at Zhejiang University. He completed Ph.D from Charité-University Berlin and Humboldt University. He completed M.D and Master of Clinical Science from Nankai University, Tianjin. He received certification from Chinese Board of Surgery. He received Research fellowship Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston. He was awarded by Ministry of Education for the 2013 Award for College Outstanding Achievement.

Immunology, Clinical Investigation, Traumatology, Nephrology

Paul L. Hermonat completed his Ph.D. at the University of Florida in 1984, and postdoctoral studies at the National Institutes of Health. He is a professor of Internal Medicine and OB/GYN at the University of Arkansas for Medical Sciences and a Research Career Scientist at the Central Arkansas Veterans Healthcare System. He was the first to generate recombinant adeno-assocociated virus (AAV/NeoR) and to transfer genes into cells via this method. He has over 140 manuscripts published, mostly on the topic of AAV molecular biology and gene transfer.

gene therapy, molecular biology

Johan was appointed Chief Scientific Officer of the Cell Therapy Catapult in May 2013. As Chief Scientific Officer, he is responsible for external scientific relations, assessment of candidate projects and technical oversight of preclinical programs. He has extensive experience of the life sciences industry, having worked in cell and tissue companies in Europe and the US for over 15 years. Johan has been involved in numerous transactions and collaborations, establishment of scientific facilities, and the management of scientific programs in industry and academia. He has published more than 60 full length scientific papers.

Stem cells, Regenerative medicine.

Munis Dundar was born in 1961. He graduated from Faculty of Medicine, Erciyes University (Turkey) in 1985. He obtained his Ph.D in Genetics from the Glasgow University (UK) in 1994 and M.D in Clinical Genetics in Faculty of Medicine, Osmangazi University (Turkey). He is president of the European Biotechnology Thematic Network Association (EBTNA). He is a board of he European Predictive, Preventive and Personalized Medicine Association (EPMA) and EPMA Journal.

His Research of Interest are Biotechnology, Cancer, Medicine etc.

Nagy Habib, Professor of Hepatobiliary Surgery at Imperial College London is a translational researcher who pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, and the use of plasmid gene therapy in hydrodynamic gene delivery. He was also the first to publish from the West a clinical trial on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency. He has published on the evolution of molecular biology of tumours (oncogene, tumour suppressor gene, epigenetic modification), gene therapy, stem cell therapy, saRNA and RNAaptamers.

liver cancer and its treatment, tumors from oncogene, tumor suppressor gene, epigenetic modification, genetherapy, stem cell therapy, RNA (Ribonucleic acid) and saRNA (small activating RNA) and RNA aptamers.

Giulio Maria Pasinetti is the Saunders Family Chair and Professor of Neurology (Mount Sinai) and Director of Basic and Biomedical Research and Training (GRECC, Bronx VA Medical Center). His research on co-morbidities influencing neurodegeneration has made him one of the top experts in his field. His principal focus is the prevention of neurodegenerative disorders even before the disease becomes symptomatic and drug discovery and screening. He is the recipient of many awards, including the Zenith and Temple awards from the Alzheimer’s Association and the Faculty Council Award for academic excellence at Mount Sinai. Dr. Pasinetti is the recipient of over 30 grants and has published over 300 groundbreaking manuscripts.

His research on co-morbidities influencing neurodegeneration has made him one of the top experts in his field. His principal focus is the prevention of neurodegenerative disorders even before the disease becomes symptomatic and drug discovery and screening.

Vasiliki E. Kalodimou MSc, Ph.D is the director of the Flow Cytometry-Research and Regenerative Medicine Department at IASO Hospital in Athens, Greece. She has studied and worked with progenitor cells from placenta, umbilical cord, and adipose tissue along with their applications in regenerative medicine and flow cytometry, with publications in the field, including research fellowships. She has published 2 books about flow cytometry, the Greek edition was published in 2010 and in 2013 the book was published from AABB Press USA. She is a Flow Cytometry Specialist, Associate Leader at AABB CT Subsection: CT Product Manufacturing and Testing, USA, Scientific Consultant in Regenerative Plastic Surgery Institute / Pure Aesthetics, Brazil, AABB Assessor, USA, editor in 3 scientific journals and her biography was included in Who Is Who in the world 2014 & 2015edition.

She has studied and worked with progenitor cells from placenta, umbilical cord, and adipose tissue along with their applications in regenerative medicine and flow cytometry.

Venkatachalam K.V. is a professor in Department of Biochemistry at Nova Southeastern University, USA

His Research Interest is Cancer, Molecular Biology etc

Dr. Nady Golestaneh is an Assistant Professor at Georgetown University School of Medicine Department of Biochemistry and Molecular Cellular Biology She received her PhD and MS degrees in Biology and Pharmacology of Aging from University of Paris VI Pierre et Marie Curie in Paris France and her BS in Cellular Biology and Biochemistry from University of Paris VII Jussieu in Paris France She performed postdoctoral training at NIH NEI and Johns Hopkins University before joining Georgetown University School of Medicine in 2005 Recently she has shown that male germline stem cells can become pluripotent capable of differentiating into the three primordial germ layers offering the possibility of autologous cellbased therapy in degenerative diseases In parallel Golestaneh’s lab has demonstrated that the iPS cells can be differentiated into functional retinal pigment epithelium that could be prominent candidates for regeneration therapies in agerelated macular degeneration AMD Dr Golestaneh’s innovative work in the area of stem cells research has earned her several prestigious national and international awards and her research is supported by NIH grant.

Her area of research interest is mainly on stem cells, autologous cellbased therapy in degenerative diseases

Dr. Uday Kishore, a cellular and molecular immunologist, is the Director of the Centre for Infection, Immunity and Disease Mechanisms, Brunel University, London. He researches on the role of innate immunity in a range of disease processes and therapeutic interventions. He earned his MSc and PhD from University of Delhi, India. He has previously been a NASA Fellow at Salk Institute, USA, MRC Fellow at Oxford, and Humboldt Fellow in Germany. He has authored over 100 research papers, 20 book chapters, 2 patents and edited 3 books. He is also the recipient of MRC Inventor’s prize, European Commission Young Scientist prize, and, more recently, Mother Teresa Excellence Award 2014.

cellular and molecular immunology

Samir A Farghaly is a Physician/Scientist,  and faculty member of the Medical College of Cornell University and The New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his PhD Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewers of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer. Mutant BRCA1 and BRCA2 genes profiles in ovarian cancer. Proteomic profiling of metastatic genes of ovarian cancer. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer.

Paul L. Hermonat completed his Ph.D. at the University of Florida in 1984, and postdoctoral studies at the National Institutes of Health. He is a Professor of Internal Medicine and OB/GYN at the University of Arkansas for Medical Sciences and a Research Career Scientist at the Central Arkansas Veterans Healthcare System. He was the first to generate recombinant adeno-associated virus (AAV/NeoR) and to transfer genes into cells via this method. He has over 140 manuscripts published, mostly on the topic of AAV molecular biology and gene transfer.

Internal Medicine, Therapeutics

Yinling Hu did her undergraduate degree in Chinese Academy of Medical Science and received Ph.D. from University of Melbourne at Australia. She was a postdoctoral fellow in Michael Karin\\\'s laboratory, University of California at San Diego from 1996 to 2001. She began to establish her laboratory as an Assistant Professor at Science Park Research Division, MD Anderson Cancer Center in November 2001 and came to NCI-Frederick as a Principal Investigator in September 2008.

Yinling Hu research interests are to understand the physiological activities of IKKα in skin tumorigenesis and inflammation and reveal the mechanisms of how IKKα regulates these function by using genetic animal models, including Ikkα conditional knockout, Ikkα kinase inactive knockin, and IKKα transgenic mice, and molecular biology approaches.

Farid Menaa (Bsc. Eng., Bsc. Bio., Msc. Genetics, Master Gerontology/Geriatry, Ph.D. Radiation Oncology and Gerontology, three international post-doctoral terms, EMBA Entrepreneurship and MD candidate), is an experienced and skilled inter- and multi-disciplinary professional. Professor, Consultant, Researcher, Principal Investigator, Executive Director, Advisor, Editor, Reviewer, Event Organizer and Entrepreneur, he earned his degrees with high distinctions from prestigious universities and institutions.He Was selected as a NIH post-doctoral fellow in Oncology (San Diego, California, USA; 2004-2007). Then, he pursued his career in Dermatology, and Stem Cells as a DFG post-doctoral Fellow (Wuerzburg, Germany; 2007-2009). Subsequently, Dr. Menaa was promoted to Chief Scientific Officer and Executive Vice-President R&D at Fluorotronics, Inc. (CA, USA; 2009-2010), a nanotechnology and fluorine chemical company. Eventually, Dr. Menaa was appointed Principal Investigator in Hematology and Genomics as a FAPESP post-doctoral Fellow (São Paulo, Brazil; 2010-2012). He was recently nominated for “Who´s is Who in the World”. He authored more than 100 publications (including peer-reviewed ISI research and review articles, books, textbooks, book chapters, conference proceedings, patents), and is the recipient of several awards.

Oncology, Gerontology, Genetics, Nutrition, Fluorine Chemistry, Biochemistry, Cell and Molecular Biology, Stem cells, Pharmaceutical Sciences, Regenerative medicine, Personalized Medicine, Translational Medicine, Integrative Medicine, Pharmacy, Nanobiotechnology and Nanomedicine

Nayernia received a Ph.D. in molecular genetics from the Medical faculty of the Georg-August University in Goettingen and Bonn/Germany. He got his associate professorship (Habilitation) in molecular human genetics from the Medical Faculty, University of Goettingen in Germany. In June 2006 he moved from Germany to UK to lead stem cell section at the University of Newcastle and got the title of Professor of Stem Cell Biology.

Professor Nayernia’s research focus is molecular mechanisms of human genetic diseases, germline stem cells, cancer stem cells, pluripotent stem cells and tissue regeneration. His lab was the first lab where derived embryonic stem cell like cells from adult germline stem cells and derived the first functional sperm cells from embryonic stem cells. His findings were reported world-wide by several News agencies.

Peshwa currently serves as EVP, Cellular Therapies at MaxCyte. Previously, he was Limited Partner and EVP, R&D at NewNeural LLC (Lisle, IL); VP of Process Sciences and VP of Manufacturing at Dendreon Corporation (Seattle, WA). Dr. Peshwa obtained his Ph.D. from the University of Minnesota (Minneapolis, MD) and B.Tech. from the Indian Institute of Technology (Kanpur, India), both in Chemical Engineering. He has published ~40 papers; is co-inventor on ~8 issued patents and applications; served in Editorial capacity for Cytotechnology and Biotechnology & Bioengineering; and serveson Advisory Board for start-up companies, Research Institute and a Venture Capital firm.

Cellular Therapies, Bioengineering

Morayma Reyes has received her MD/PhD degree from University of Minnesota in 2003. She has published more than 20 papers in reputed journals and is serving as an editorial board member and reviewer of reputed journals. She has been nominated and awarded multiple Junior Faculty Awards. Dr. Reyes is currently an assistant professor in the Departments of Pathology and Laboratory Medicine in the School of Medicine and Oral Health Science in the Dental School at the University of Washington.

Adult stem cells, Stem cell therapy for muscular dystrophy, Stem cell homing and migration, Tissue regeneration, Bioengineering, Stem cells, Vascular Biology, Angiogenesis

Venkatachalam K.V. is a professor in Department of Biochemistry at Nova Southeastern University, USA

His Research Interest is Cancer, Molecular Biology etc

Raj Kumar, Ph.D. is a professor of Biochemistry in the Department of Basic Sciences at The Commonwealth Medical College (TCMC), Scranton, PA. Dr. Kumar received his Ph.D. degree from University of Lucknow, India and was a postdoctoral fellow at the University of Texas Medical Branch (UTMB), Galveston, TX. Before moving to TCMC, Dr. Kumar held a position of Associate Professor in the department of Internal Medicine at UTMB, Galveston, TX. He is a basic researcher with a long-standing interest in examining the role of structural dynamics of steroid hormone receptors in gene regulation in physiology and diseases, and has an extensive list of publications in this area in highly reputed peer reviewed journals. Dr. Kumar has trained a number of students and postdoctoral fellows in his laboratory. Dr. Kumar has served as a reviewer for about 40 scientific journals, and several national and international grant review panels.

Structure and functions of transcription factors; Protein Folding & Biophysics; Macromolecular Interactions; Cell Signaling and Gene Regulation; Post translational modifications

Jianfeng Lu was born in a small town in China. He likes Biology and Medicine since he was in Mid-school. He treat biology and medicine research as one of the greatest jobs in the world. He is proud of being a bio-medical researcher, because he think through my research, maybe he could do something really good for the whole human beings. Now he is focusing on the research on induced pluripotent stem cells, induced neural cells and neural degeneration diseases. He hopes that he can share the knowledge with the world and make something translated into clinical medicine to help the patients out of pain.

During more than ten years of clinical and biomedical study, He gradually focuses his research area in Stem cells and Neurosciences, which he treats as an important and essential component for Regeneration Medicine. As for the Stem cells part, He is interested in generation of pluripotent stem cells (iPSCs), generation of induced neural stem cells (iNP/iNSC) and generation of induced precursors of some neuronal subtypes, such as serotonin neuron precursors (i5-HTP); And at the same time, he is trying his best to uncover the mechanism behind the phenomenon. He took charge in the iPSC core at Waisman center in University of Wisconsin-Madison from 2009 to 2011 and played the role as one of the advisors of iPSC Service in 2012, in which he generated more than 28 iPSC cell lines from different patients, such as Down Syndrome (DS), Spinal Muscular Atrophy (SMA) and Rett Syndrome (RS). They use patients’ iPSC derived neurons or glial cells to compare with the wild type target cells, and then find the differences in phenotypes and functions. With some compounds treatment or genetic modification, he could rescue some important phenotypes in the in vitro system, which potentially could help the discovery of new targets to treat the patients and the screening of new drugs for therapy. They really hope via this approach, we could find some efficient ways to treat the patients with neural degeneration diseases. As for the Neurosciences part, He is interested in neural differentiation and specification. He did some research on mouse embryonic stem cells and its neural differentiation. Through experiments, they found that retinoic acid (RA) could promote neural lineage entry by ESCs in adherent monolayer culture systems and this effect depends on RA signaling and its crosstalk with the ERK and Wnt pathways. Recently, they use human pluripotent stem cells (PSC) to generate many subtypes of neurons and glial cells. Beside the phenotype comparison between normal persons and patients which are mentioned above, they also use these PSC-derived- neurons or glial cells to transplant into the animal models to see the cell-therapy effects, especially for some cell-type deficient neural diseases, such as Parkinson’s disease (PD). He is still learning from others and the work. He hopes one day he could really bring some useful information to those patients and help them to relief some pain.

Evan Y. Snyder earned his M.D. and Ph.D. from the University of Pennsylvania. He completed residencies (including serving as Chief Resident) in pediatrics and neurology as well as a clinical fellowship in neonataology at Children & middots Hospital-Boston, Harvard Medical School. He became a faculty physician in the Department of Pediatrics, Children & middots Hospital-Boston and while serving as a research fellow in the Department of Genetics, Harvard Medical School. He established a lab at Children & middots Hospital-Boston in 1992. In 2003, Dr. Snyder was recruited to the Burnham Institute for Medical Research as Professor and Director of the Program in Stem Cell & Regenerative Biology. He then inaugurated the Stem Cell Research Center and initiated the Southern California Stem Cell Consortium. He serves on multiple editorial boards, published extensively in the stem cell literature, holds multiple patents in the stem cell space, and received numerous honors and lecturers widely and internationally.

Fundamental stem cell biology
Developmental neuroscience
Neural transplantation
Developmental biology
Cellular (in vitro) and animal models of disease Differentiation of pluripotent and multipotent stem cells
Neurodegenerative diseases
Neural injury and repair
Ethics and public policy
Science education

Samy L Habib is an Assistant Professor of the Department of Medicine, The University of Texas, Health Science Center, San Antonio, USA, and has strong background in molecular carcinogenesis, with specific training and expertise in several research areas. He was a co-investigator on several previous and current projects funded by ADA, NKF, AHA, VA and NIH. Attesting to his national visibility, he has been selected to serve as a regular reviewer for the Medical Research Program of the Department of Defense and Editorial Board Member of 2 Journals.

Carcinogenesis in diabetes, Mutations in DNA repair gene in diabetes and cancer,Role of Tuberin in Neuronal Degeneration,Role of Tuberin in Renal Hypertrophy and Fibrosis, Role of Tuberin in Tumorigenesis, Role of tuberin/mTOR pathway in apoptosis. (1) Understanding the role of oxidant stress in the pathogenesis of renal cell carcinoma (2) Screening cancer and diabetic patients for DNA repair gene mutation(s) (3) Explore the mechanism of renal hypertrophy and fibrosis in diabetic patients (4) Study the mechanism by which TSC2 gene regulates the DNA damage (8-oxodG) and repair (OGG1) pathways and other signal transduction including cell cycle proteins in the pathogenesis of renal carcinogenesis (5) study the role of tuberin/mTOR pathway in apoptosis in diabetes (6) Study the role of tuberin/mTOR pathway in the regulation of the neuronal damage in Alzheimers diseases (AD) and Parkinson diseases

Ivan Rich obtained his Ph.D in 1978 at the University of Ulm, in Germany and performed his postdoctoral studies at the University of Chicago. Prior to starting HemoGenix, a contract services and assay development company in 2000 where he is CEO, he was Director of Basic Research in the Division of Bone Marrow Transplantation and Professor at the University of South Carolina. He has published 50 peer-reviewed articles and edited two books. His primary field of expertise is in developmental, experimental and applied clinical hematology.

Developmental, experimental and applied clinical hematology

Marek Malecki MD PhD is President of Phoenix Biomolecular Engineering Foundation, Chief Executive Officer of the Center for Molecular Medicine, and Visiting Professor at the University of Wisconsin. He earned MD degree at the Medical Academy, Poznan followed by Residency/Fellowship in Molecular Medicine in Rigshospitalet, Copenhagen. He earned PhD at the National Academy of Sciences, Warsaw followed by the postdoctoral fellowships in molecular biology at the Austrian Academy of Sciences, Karolinska Institutet, Stockholm, Salzburg and Vienna, ETH, Zurich, Utrecht University Medical School, Utrecht, Cancer Center, Vienna, Cancer Center, Amsterdam, Biozentrum, Basel. Dr Malecki developed a novel technology to identify and isolate single living pluripotent stem cells followed by their clonal expansion and molecular profiling including sequencing their proteomes, transcriptomes, and genomes. This technology serves also for reprogramming the stem cells for their use as the vectors in gene therapy of cancer. The technology, protected by the US and WIPO, is currently streamlined to clinical trials. He is the first author on the peer-reviewed articles. He is often an invited speaker and courses faculty at the international professional conferences. Dr Malecki is Editor in Chief of the Journal of Genetic Syndromes and Gene Therapy and member of the Editorial Boards for many high-impact professional journals. He is the member of the American Medical Association, American Association of Human Genetics, American Antibody Society, Southern California Biotechnology Council, and Rho Chi Honor Society for Excellence in Teaching and as the Faculty Role Model.

Cancers of ovaries, cancers of testes, cancer stem cells (CSC), circulating tumor cells (CTCs), genetic disorders, iatrogenic genetic mutations, gene therapy, targeted gene delivery, fertility sparing therapy, biobanking, in vitro fertilization

Samir A Farghaly is a Physician/Scientist, and faculty member of the Medical College of Cornell University and the New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his PhD Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewer of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer. Mutant BRCA1 and BRCA2 genes profiles in ovarian cancer. Proteomic profiling of metastatic genes of ovarian cancer. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer.

Eldad Zacksenhaus is an Associate Professor in the Department of Medicine, Department of Laboratory Medicine & Pathobiology and the Department of Medical Biophysics, University of Toronto.

Breast cancer and the tumor suppressor pRb pathway.

Song Xin is working as a Professor in the Third Affiliated hospital, Kunming Medical College, China.

Signal transduction, Cell Cycle Biochemotherapy and Molecular Carcinogenesis. Preclinical/clinical development of molecularly targeted cancer therapeutic agents and signaling networks, including molecular mechanism studies in vitro and in vivo of therapeutic agents and molecular carcinogenesis. Current research mainly focuses on investigation of the molecular and signaling transduction pathways. Most agents are the regulators of signal transduction, cell cycle, apoptosis, angiogenesis, metastasis, differentiation, proteasome inhibition and DNA damage. Signal transduction including post translational modifications (acetylation, methylation, phosphorylation, cleavage) and molecular biologic events. The main signal transduction pathways he has studied are Ras/Raf/MEK/Erk, PKC/MAPK, PI3K/PKB/GSK3, (NFk-B, PKA, proteasome, differentiation, cell cycle, caspase, cell death receptor, cell growth receptor) etc.

Kapil Bharti obtained his Ph.D. from Johann Wolfgang Goethe University in Frankfurt, Germany, graduating summa cum laude. His Ph.D. work involved research in the areas of heat stress, chaperones, and epigenetics. He did his postdoc at the NIH, where he published numerous papers in the areas of transcription regulation, pigment cell biology, and developmental biology of the eye. He has won several awards, including, most recently, being a finalist in the prestigious trans-NIH Earl Stadtman Tenure-Track Symposium. His current work as the Head of the Unit on Ocular Stem Cells and Translational Research at NEI, NIH involves developing cell-based therapy for retinal degenerative diseases using induced pluripotent stem cell technology.

Stem Cell, Epigenetics, Cancer

Paul L. Hermonat completed his Ph.D. at the University of Florida in 1984, and postdoctoral studies at the National Institutes of Health. He is a professor of Internal Medicine and OB/GYN at the University of Arkansas for Medical Sciences and a Research Career Scientist at the Central Arkansas Veterans Healthcare System. He was the first to generate recombinant adeno-assocociated virus (AAV/NeoR) and to transfer genes into cells via this method. He has over 140 manuscripts published, mostly on the topic of AAV molecular biology and gene transfer.

AAV molecular biology and gene transfer

Eric Halioua is CEO at Promethera Biosciences, a biotechnology company that discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way. He was also a Board Member of a French biotechnology company called Vivalis, which specializes in the production of avian stem cells lines for the production of vaccines and recombinant proteins.

Corporate strategy, marketing, business development and licensing-in/out, founder of biotechnology companies

Richard G. Pestell, MB, BS, MD, PhD, MD (Hon. Causa), FACP, FRACP, MBA, Director, Kimmel Cancer Center, Vice President, Oncology Services, Associate Dean, Cancer Programs, Chairman, Department of Cancer Biology. Dr. Pestell received his MD (MBBS) from the University of Western Australia and his PhD degree from the University of Melbourne. He undertook post doctoral and clinical training in Hematology/Oncology and Endocrinology. As the single Australian recipient of the Royal Australian College of Physicians Winthrop traveling scholar and Neil Hamilton Fairley Scholar (1991-1994), he continued research at Harvard University and served as clinical fellow at Massachusetts General Hospital. Prior to his current position at the Kimmel Cancer Center, Dr. Pestell was Director of the Lombardi Cancer Center, Associate Vice President of the Medical Center at Georgetown University and Board member of the Georgetown University Hospital in Washington, DC. Dr. Pestell has authored 388 original publications and book chapters and 187 published abstracts. His work is highly cited (~27,500 citations, H-index:88). His papers have been published in prominent peer reviewed journals including Cell, Science, Nature Medicine, Molecular Cell and EMBO J. In March 2002, he was ranked first in the world for increase in total scientific impact in biology and first in the world for biochemistry (ISI). Dr. Pestell is funded as the Principal Investigator of six RO1 grants and Principal Investigator of the Kimmel Cancer Center CCSG grant. Dr. Pestell has received a number of awards for his scientific discoveries in breast and prostate cancer, including the Harrison Award (highest award of the Australian Endocrine Society), Fellow of the Royal Society of Medicine(UK), Doctor HonorisCausa, (University of Western Australia), elected membership to the American Society of Clinical Investigators, the Irma T. Hirschl Weil Caulier Career Scientist Award, Diane Belfer Faculty Scholar in Cancer Research, the Pfeiffer Award, and elected fellow to the American Association for the Advancement of Science. Dr. Pestell serves as a reviewer for 11 funding agencies and has been an active member of NIH study sections (RO1, SPORES, Cancer Centers, Program projects). Dr. Pestell has been a reviewer for 25 distinct scientific journals (currently an active editorial board member of seven journals) and has served on the externaladvisory board of six NCI-designated cancer centers.

Cancer, Molecular Biology

Munis Dundar was born in 1961. He graduated from Faculty of Medicine, Erciyes University (Turkey) in 1985. He obtained his Ph.D in Genetics from the Glasgow University (UK) in 1994 and M.D in Clinical Genetics in Faculty of Medicine, Osmangazi University (Turkey). He is president of the European Biotechnology Thematic Network Association (EBTNA). He is a board of the European Predictive, Preventive and Personalized Medicine Association (EPMA) and EPMA Journal. He has published more than 60 papers in reputed journals.

His Research ineterest is Clinical genetics, molecular biology, genetics.

Jagat R Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both, academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer. Dr. Kanwar has published 55 research articles, 12 invited reviews and 5 book chapters, in highly ranked, international, peer-reviewed journals. These publications have added to the body of knowledge in the fields of immunology, cancer gene therapy, nanomedicine, cell biology and biotechnology, and have extended these disciplines. He is a key inventor on 9 international patents and has provided consultancy to 5 Biotechnology based companies. He is a member of editorial board for 7 international journals and a nominated member of more than 12 national and international societies including American Society of Nanomedicine. He has extensive and close collaborations with colleagues from New Zealand, Australia, Singapore, India, China and USA.

Nanotechnology based drug delivery of proteins/peptides, siRNA and miRNA to target cancer and chronic inflammation drug discovery for novel anticancer targets for cancer cell survival, death, arrest, and repair development of immunomodulatory and anti-inflammatory bioactives, proteins and peptides for neuroprotection development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of solid tumours (colon and breast cancers)

Hilal Arnouk, MD, PhD is the Director of Research and Development at Cell Constructs, Inc. affiliated with Georgia State University. He has received his education and post-doctorate training at Roswell Park Cancer Institute, Medical College of Georgia and University of Alabama at Birmingham. His major areas of expertise include Cancer Immunotherapy, Biomarker Discovery, Stem Cells and Regenerative Medicine. He recently edited a book on Tumor Immunotherapy and Cancer Vaccines.

Cancer, Stem Cells, Regenerative Medicine, Immunotherapy

Drapeau holds a Bachelor’s degree in Honors Neurophysiology and a Master’s degree in Neurology and Neurosurgery from Canada’s McGill University in Montreal, Quebec, with work performed at the Montreal Neurological Institute. His thesis was on epileptogenesis and the role of eicosanoids in long-term potentiation and he completed further scientific training in variable projection microscopy at Bradford Research Institute and in ion-selective microelectrode recordings at St-Anne Hospital in France. Mr. Drapeau has been the Director of Research and Development at Cell Tech International and then Desert Lake Technologies, before co-founding STEMTech HealthSciences and becoming its Chief Science Officer. He is the author of the Stem Cell Theory of Renewal, detailed in his book Cracking the Stem Cell Code.

His interest focuses on basic and clinical research pertaining to adult stem cells, and more specifically the natural role of stem cells in the body and clinical potential of Endogenous Stem Cell Mobilization (ESCM).

Mahendra Rao joins The New York Stem Cell Foundation Research Institute as the Vice President for Regenerative Medicine. Dr. Rao brings decades of experience in stem cell science and business development to NYSCF's mission to translate stem cell research into cures. Dr. Rao was the Director of the NIH Center for Regenerative Medicine since its founding in 2010. Prior to joining the NIH, Dr. Rao spent six years as the vice president of Regenerative Medicine at Life Technologies, Inc.

He has over twenty years of experience in all aspects of the stem cell field including government, academia, and business.

Davis is a graduate of Harvard Medical School and had his postgraduate medical training at Albert Einstein College of Medicine and the NIH. His academic positions have included Chair, Department of Medicine, Albany Medical College. He has served as President, American Thyroid Association, as a member of the Board of Directors of the American Board of Internal Medicine and he is Co-Head, Faculty of 1000 – Endocrinology. He serves on multiple Editorial Boards of His scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells. He has co-authored more than 200 original research articles and 30 textbook chapters and he has edited three medical textbooks.

Paul J. Davis's scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells

Haval Shirwan is Dr. Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, Professor of Microbiology and Immunology, Director of Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his Graduate studies at the University of California in Santa Barbara, CA, and Postdoctoral studies at California Institute of Technology in Pasadena, CA. He joined the University of Louisville in 1998 after holding academic appointments at various academic institutions in the United States. He is member of several national and international societies and recipient of various awards.

Dr. Haval Shirwan research focuses on the modulation of immune system for the treatment of immune-based diseases with particular focus on type 1 diabetes, transplantation, and development of prophylactic and therapeutic vaccines against cancer and infectious diseases. He is an inventor on over a dozen of worldwide patents, widely published, organized and lectured at numerous national/international conferences, served on study sections for various federal and non-profit funding agencies, and is on the Editorial Board of a dozen of scientific journals.

Khalid Shah is an Associate Professor at Harvard Medical School and directs the Molecular Neurotherapy and Imaging Laboratory at Massachusetts General Hospital in Boston, MA. He is also the Director of the Stem Cell Therapeutics and Imaging program in MGH's Center for Translational Research, and is a Principal Faculty at Harvard Stem Cell Institute in Boston. Dr. Shah's recently published works are two books featuring current groundbreaking insights into stem cell therapies for cancer, Stem Cell Therapeutics for Cancer (Wiley-Blackwell 2013), and Mesenchymal Stem Cells in Cancer Therapy (Elsevier 2014). The potential of developing novel cancer therapies by him and his team has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from Alliance for cancer gene therapy (ACGT), Research fellow award from American Cancer Society (ACS), Distinguished research award from Academy of Radiology and Innovation awards from James McDonnell Foundation, American Brain Tumor Association (ABTA) and Goldhirsh foundation. Additionally, Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who recently awarded him the Harvard Young Mentor Award.

In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.

Diana Anderson completed her PhD in the Faculty of Medicine University of Manchester, UK. She currently holds the Established Chair in Biomedical Sciences at the University of Bradford. She has published over 450 papers and eight books. She has served on 10 editorial boards, has supervised 30 PhD students and is Editor- in- Chief of the Book Series “Issues in Toxicology” for the Royal Society of Chemistry. She has hosted and participated in 56 meetings for the WHO on Chemical Safety. She has been a Vice President of the Institute of Biology.renowned nephropathologist with over 35 years of experience in renal pathology. Having received his Doctor of Medicine at the University of Puerto Rico, he has over 30 years of research on renal damage associated with multiple myeloma. Before becoming the Chair of Pathology of LSU Health Shreveport, Dr. Herrera was the Medical Director of Nephrocor, a private renal pathology laboratory. He has served as Professor and Chair at St. Louis University as well as Director of Surgical Pathology at both the University of Alabama and the University of Mississippi. Dr. Herrera is a retired Colonel with the U.S. Army. He is also a Professor in the Department of Anatomy and Cell Biology at LSU Health in Shreveport.

cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology, general toxicology

Dennis M. Lox M.D is the Director of the Sports and Regenerative Medicine Centers A Stem Cell Center of Excellence in the Washington D.C. Metro Area and the Tampa Bay Metro Area. Dr. Lox attended the University of Arizona, where he was Phi Beta Kappa studying Liberal Arts. Dr. Lox then completed his medical training at Texas Tech University, followed by his residency program in PM&R at The University of Texas Health Science Centers at San Antonio. Dr. Lox has always pursued Sports Medicine, and this led to a path into Regenerative Medicine.

Lox has always pursued Sports Medicine, and this led to a path into Regenerative Medicine.

Esma S. Yolcu is Assistant Professor of Microbiology and Immunology and the Director of Imaging Facility at the Institute for Cellular Therapeutics and member of James Brown Cancer Center, University of Louisville, Louisville, KY. Dr. Yolcu received her Ph.D. degree from University of Ankara, Ankara, Turkey and joined the University Of Louisville School Of Medicine in Louisville, KY, to pursue her postdoctoral training. Dr. Yolcus research focuses on novel immunomodulatory approaches for the induction of tolerance to auto and alloantigens for the purpose of treating rejection and autoimmunty. Dr. Yolcu is the recipient of several awards, member of various national and international societies, serves on Editorial Board of scientific journals, and published over 67 peer-reviewed papers, abstracts, and review articles in high ranking journals, such as Immunity, Circulation, Blood, and the Journal of Immunology.

Dr. Yolcu’s research interests include developing strategies to induce tolerance to auto and alloantigens for the purpose of treating autoimmune diseases and preventing allograft rejection. She co-pioneered a novel technology described as ProtEx™ with Dr. Shirwan as a practical alternative to gene therapy to display immunoregulatory molecules on the surface of bone marrow cells and use such engineered cells as a means of immunomodulation to establish mixed allogeneic hematopoietic chimerism under non-myeloablative conditions without graft-related toxicity such as graft versus host disease.

Mei Wan is an Associate professor of the Center for Musculoskeletal Research, Department of Orthopaedic Surgery at Johns Hopkins University School of Medicine. She obtained her Ph.D. in Pathophysiology at Hebei Medical University in 1997. In recent years, she found that active TGFβ can be released from tissue in response to perturbations to the local environment such as bone remodeling (Nat. Med. 2009, Cell Stem Cell 2011), arterial injury (Stem Cells 2012, Stem Cell Dev. 2014), and lung injury (J. Immunol. 2014). The released active TGFβ stimulates the migration of MSCs to participate in tissue repair or remodeling. Currently, Dr. Mei Wan is an editorial board member for Journal of Bone and Mineral Research and Bone Research.

Mei Wan has a research experience from the past 17 years, her focuses is on characterizing the mechanisms by which bone marrow mesenchymal stem cells (MSCs) are regulated in various physiological and pathological conditions such as bone remodeling, cancer development, vascular disorders, and tissue repair/remodeling. At earlier years of her career, she demonstrated that the role of proteosome degradation pathway in the regulation of TGFβ signaling. She also identified the central mechanism through which parathyroid hormone stimulates bone formation, which had been the major unresolved question in bone field.

Margarita Glazova, received the Ph.D. (1997) fromSechenovInstitute of Evolutionary Physiology and Biochemistry, Russian Academy of Science and postdoctoral fellow of Adj. Professor P.Koskinen, Turku Centre for Biotechnology, University of Turku/ÅboAkademi, Finland (2001-2003). She was a Research Associate of Prof. A.K.Murashov, East Carolina University Brody School of Medicine, Department of Physiology, Greenville, NC, USA (2004-2006).

She is a Senior Researcher at the Laboratory of Comparative Somnology and Neuroendocrinology, Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St.Petersburg, Russia. She has published more than 30 articles in peer-reviewed scientific journals

Haval Shirwan is Dr. Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, Professor of Microbiology and Immunology, Director of Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his Graduate studies at the University of California in Santa Barbara, CA, and Postdoctoral studies at California Institute of Technology in Pasadena, CA. He joined the University of Louisville in 1998 after holding academic appointments at various academic institutions in the United States. He is member of several national and international societies and recipient of various awards.

His research focuses on the modulation of immune system for the treatment of immune-based diseases with particular focus on type 1 diabetes, transplantation, and development of prophylactic and therapeutic vaccines against cancer and infectious diseases. He is an inventor on over a dozen of worldwide patents, widely published, organized and lectured at numerous national/international conferences, served on study sections for various federal and non-profit funding agencies, and is on the Editorial Board of a dozen of scientific journals.

Davis is a graduate of Harvard Medical School and had his postgraduate medical training at Albert Einstein College of Medicine and the NIH. His academic positions have included Chair, Department of Medicine, Albany Medical College. He has served as President, American Thyroid Association, as a member of the Board of Directors of the American Board of Internal Medicine and he is Co-Head, Faculty of 1000 – Endocrinology. He serves on multiple Editorial Boards of His scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells. He has co-authored more than 200 original research articles and 30 textbook chapters and he has edited three medical textbooks.

Paul J. Davis's scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells

Drapeau holds a Bachelor’s degree in Honors Neurophysiology and a Master’s degree in Neurology and Neurosurgery from Canada’s McGill University in Montreal, Quebec, with work performed at the Montreal Neurological Institute. His thesis was on epileptogenesis and the role of eicosanoids in long-term potentiation and he completed further scientific training in variable projection microscopy at Bradford Research Institute and in ion-selective microelectrode recordings at St-Anne Hospital in France. Mr. Drapeau has been the Director of Research and Development at Cell Tech International and then Desert Lake Technologies, before co-founding STEMTech HealthSciences and becoming its Chief Science Officer. He is the author of the Stem Cell Theory of Renewal, detailed in his book Cracking the Stem Cell Code.

His interest focuses on basic and clinical research pertaining to adult stem cells, and more specifically the natural role of stem cells in the body and clinical potential of Endogenous Stem Cell Mobilization (ESCM).

Herrera is currently Chair of Pathology and Laboratory Director of LSU Health Shreveport, a position he has held from 1996-2006 and since 2012 until now. He is an internationally renowned nephropathologist with over 35 years of experience in renal pathology. Having received his Doctor of Medicine at the University of Puerto Rico, he has over 30 years of research on renal damage associated with multiple myeloma. Before becoming the Chair of Pathology of LSU Health Shreveport, Dr. Herrera was the Medical Director of Nephrocor, a private renal pathology laboratory. He has served as Professor and Chair at St. Louis University as well as Director of Surgical Pathology at both the University of Alabama and the University of Mississippi. Dr. Herrera is a retired Colonel with the U.S. Army. He is also a Professor in the Department of Anatomy and Cell Biology at LSU Health in Shreveport

Herrera sits on multiple national panels and has been the invited guest lecturer in over 300 domestic and international venues. He has authored more than 280 articles and chapters. His main interest includes understanding of pathogenesis of renal disorders occurring in patients with plasma cell dyscrasias and has engaged in exploring glomerular repair using stem cells. He has received the “Tatiana T. Antovych, M.D. Award” from the Armed Forces Institute of Pathology/American Registry of Pathology for contributions to renal pathology. He is the recipient of a grant from the Amyloidosis Foundation to study glomerular repair in AL-amyloidosis using mesenchymal stem cells.

Simon Berkovich received MS in Applied Physics from Moscow Physical-Technical Institute (1960) and PhD in Computer Science from the Institute of Precision Mechanics and Computer Technology of the USSR Academy of Sciences (1964). He played a leading role in a number of advanced computer systems projects. He has several hundred publications in various areas of physics, electronics, computer science, and biology. In 2002, Professor Simon Berkovich was elected a member of the European Academy of Sciences "for an outstanding contribution to computer science and the development of fundamental computational algorithms". In 2014, he won the GWU Technology Transfer Innovation Competition.

He has several hundred publications in various areas of physics, electronics, computer science, and biology. In 2002, Professor Simon Berkovich was elected a member of the European Academy of Sciences "for an outstanding contribution to computer science and the development of fundamental computational algorithms". In 2014, he won the GWU Technology Transfer Innovation Competition.

Dennis M. Lox M.D is the Director of the Sports and Regenerative Medicine Centers A Stem Cell Center of Excellence in the Washington D.C. Metro Area and the Tampa Bay Metro Area. Dr. Lox attended the University of Arizona, where he was Phi Beta Kappa studying Liberal Arts. Dr. Lox then completed his medical training at Texas Tech University, followed by his residency program in PM&R at The University of Texas Health Science Centers at San Antonio. Dr. Lox has always pursued Sports Medicine, and this led to a path into Regenerative Medicine.

Lox has always pursued Sports Medicine, and this led to a path into Regenerative Medicine.

Diana Anderson completed her PhD in the Faculty of Medicine University of Manchester, UK. She currently holds the Established Chair in Biomedical Sciences at the University of Bradford. She has published over 450 papers and eight books. She has served on 10 editorial boards, has supervised 30 PhD students and is Editor- in- Chief of the Book Series “Issues in Toxicology” for the Royal Society of Chemistry. She has hosted and participated in 56 meetings for the WHO on Chemical Safety. She has been a Vice President of the Institute of Biology.

cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology, general toxicology

Gallicchio earned his Ph.D. in Experimental Hematology at New York University Medical Center. He completed a fellowship in hematology at Memorial Sloan Kettering and Did post--‐graduate training at the University Of Connecticut Health Center. He received his Diploma in internal medicine from the “Vasile Goldis” University of Arad (Romania). He has published more than 160 scientific articles and book chapters and has received ten U.S. patents for discoveries focused on drug development for AIDS and cancer. He has served on the faculty of several American and international universities in Addition to serving as President of Alpha Eta Honor Society, the International Society For Lithium Research, and the International Federation of Biomedical Laboratory Science. He currently serves as Vice President, Educational and Research Centers in Trace Elements operated under UNESCO. He is a Fellow of the Association of Clinical Scientists, the Association of Schools of Allied Health Professions, and the Royal Society Of the Arts. In 2003, at the 200th anniversary of RSA, because of his long--‐standing effort To educate and train biomedical laboratory scientists from England, Dr. Gallicchio was recognized for his efforts by being presented to Her Majesty, Queen Elizabeth II.

Research interests include experimental drug therapeutics for AIDS and cancer with a focus on compounds that inhibit ribonucleotide reductase and anti-oxidants derived from natural food products; the non-psychiatric clinical uses of lithium, in particular for Alzheimer's disease and viral-induced pathogens; experimantal hematopoiesis, with a particular interest in stem cell biology and the role of stroma/microenvironment in these processes; international education pertaining to biomedical laboratory science.

Georg F. Weber attended medical school in Wuerzburg, Germany. He worked at the Dana-Farber Cancer Institute, Harvard Medical School from 1990 through 1999 and is currently on the faculty at the University of Cincinnati. Georg F. Weber has published close to 90 scientific reports, including many in the most respected professional journals, and various monographs, most recently textbooks on molecular oncology and anti-cancer drugs. He holds several patents.

Weber has made contributions to metastasis research by discovering the interaction between the molecules osteopontin and CD44 and by defining the physiologic role of metastasis genes as stress response genes. While he continues to address fundamental questions, he is researching new venues for diagnosis and therapy of cancer progression.

Khalid Shah is an Associate Professor at Harvard Medical School and directs the Molecular Neurotherapy and Imaging Laboratory at Massachusetts General Hospital in Boston, MA. He is also the Director of the Stem Cell Therapeutics and Imaging program in MGH's Center for Translational Research, and is a Principal Faculty at Harvard Stem Cell Institute in Boston. Dr. Shah's recently published works are two books featuring current groundbreaking insights into stem cell therapies for cancer, Stem Cell Therapeutics for Cancer (Wiley-Blackwell 2013), and Mesenchymal Stem Cells in Cancer Therapy (Elsevier 2014). The potential of developing novel cancer therapies by him and his team has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from Alliance for cancer gene therapy (ACGT), Research fellow award from American Cancer Society (ACS), Distinguished research award from Academy of Radiology and Innovation awards from James McDonnell Foundation, American Brain Tumor Association (ABTA) and Goldhirsh foundation. Additionally, Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who recently awarded him the Harvard Young Mentor Award.

In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.

Xiao is a Professor and the scientific Director in School of Pharmaceutical Sciences and Technology at Dalian University of Technology, and the Director of the Functional Genomics and Proteomics Laboratories at the Creighton University School of Medicine, and an internationally recognized expert in the field of genomics and proteomics of cancer. Dr. Xiao earns his Ph.D. in molecular computational biology at Chinese Academy of Sciences.

Xiao had his postdoctoral research trained in Baylor College of Medicine and UCLA, focusing on pharmacokinetics and biochemistry of non-steroid inflammatory drugs, and cell cycle regulation. He has been regular reviewer or ad hoc reviewer for several medical journals, different funding agency and several journal Editorial Board members and senior Editors.

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China. He is also served as a principle investigator at the Hong Kong Cancer Institute. He has authored or co-authored ~120 papers and has written a number of books or book chapters. He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents. He was educated in China and United Kingdom and has MB and PhD degrees.

He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer.

James Sherley, graduated from Harvard College (1980) and completed joint M.D./Ph.D. Degrees at the Johns Hopkins University School of Medicine (1988). After post-doctoral studies at Princeton University, beginning in 1991 he started the cancer cell molecular biology research at Fox Chase Cancer Center. In 1998, he began adult stem cell research at Massachusetts Institute of Technology, and in 2007 continued at Boston Biomedical Research Institute. In 2013, he founded the Adult Stem Cell Technology Center, LLC, (ASCTC), which he currently directs. ASCTC is developing technologies for mass-producing human tissue stem cells for applications in drug development and transplantation medicine. Honors & Awards 2006 NIH Director's Pioneer Award 2003 Ellison Medical Foundation Senior Scholar Award in Aging Research 1993 Pew Scholar Award in the Biomedical Sciences

Adult stem cells, adult stem cell expansion, adult stem cell-specific biomarkers, adult stem cell quantification, induced pluripotent stem cell production efficiency, cancer, aging, drug development, immortal DNA strands, non-random segregation, H2A.Z, epigenomics, epigenetics.

Drapeau holds a Bachelor’s degree in Honors Neurophysiology and a Master’s degree in Neurology and Neurosurgery from Canada’s McGill University in Montreal, Quebec, with work performed at the Montreal Neurological Institute. His thesis was on epileptogenesis and the role of eicosanoids in long-term potentiation and he completed further scientific training in variable projection microscopy at Bradford Research Institute and in ion-selective microelectrode recordings at St-Anne Hospital in France. Mr. Drapeau has been the Director of Research and Development at Cell Tech International and then Desert Lake Technologies, before co-founding STEMTech HealthSciences and becoming its Chief Science Officer. He is the author of the Stem Cell Theory of Renewal, detailed in his book Cracking the Stem Cell Code.

Dr. Parolini obtained her Biology degree, graduating summa cum laude, from the University of Milan in 1988. In 1994 she completed her Doctorate in Cellular and Molecular Biotechnology in Biomedicine. She worked in the field of primary immunodeficiencies at St. Jude Children's Research Hospital in Memphis, Tennessee, USA (1991-1994) and at the University of Vienna, initially as visiting scientist (1995-1998), before being promoted to Lab Head (1998-2002). In 2002, Dr. Parolini was nominated Director of the E. Menni Research Center (CREM), Fondazione Poliambulanza, Brescia, Italy, where she has pioneered research on human placenta-derived stem cells. The main lines of research at CREM are centred around amniotic and chorionic membrane-derived cells and their conditioned media, with particular focus on immunomodulatory potential in vitro, as well as in vivo assessment of anti-fibrotic effects after transplantation/injection into preclinical animal models of induced fibrosis and autoimmune diseases. Dr. Parolini has been an invited speaker at over 80 international congresses and has been a scientific leader and organizer of several international events. She is the author of over 100 publications in peer-reviewed scientific journals as well as several book chapters, and has had one patent issued while two are currently pending. She is a member of several scientific societies and is the President of the International Placenta Stem Cell Society (IPLASS).

Shirwan, Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, Professor of Microbiology and Immunology and the Director of the Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his graduate studies at the University of California in Santa Barbara, CA and postdoctoral studies at California Institute of Technology in Pasadena CA. He joined the University of Louisville in 1998 after holding academic appointments at various institutions in the United States. Shirwans research focuses on the modulation of immune system for the treatment of immune based diseases with particular focus on type 1 diabetes transplantation and development of vaccines against infections and cancer. Shirwan is widely published lectured at various National/International conferences served on various federal and nonprofit funding agencies and is on the Editorial Board of nine scientific journals He is a member of several National and International societies and the recipient of various awards.

Immunomodulation using proprietary novel recombinant proteins under clinically applicable protocols for therapeutic purposes with major focus on: Type 1 diabetes,Graft rejection,Bone marrow transplantation,Vaccines (cancer and infectious diseases)

Dr. Davis is a graduate of Harvard Medical School and had his postgraduate medical training at Albert Einstein College of Medicine and the NIH. His academic positions have included Chair, Department of Medicine, Albany Medical College. He has served as President, American Thyroid Association and as a member of the Board of Directors of the American Board of Internal Medicine. His scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He has co-authored more than 200 original research articles and 30 textbook chapters and he has edited three medical textbooks.

Dr. Davis directs a group of scientists who have defined molecular mechanisms for many nongenomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. They have described the cell surface receptor for thyroid hormone on integrin avb3 and the actions of tetraiodothyroacetic acid (tetrac) and reformulated (nanoparticulate) tetrac initiated at this plasma membrane receptor that are anti-angiogenic and anti-cancer by multiple cell surface and intracellular pathways.

Dr. Xiao is a Professor and the Director in School of Pharmaceutical Science at Dalian University of Technology China and the Functional Genomics and Proteomics Laboratories at the Creighton University School of Medicine, and an internationally recognized expert in the field of genomics and proteomics of cancer and bone disease. Dr. Xiao earns his Ph.D. in molecular biology in Institute of Biophysics at Chinese Academy of Sciences. He had his postdoctoral research trained in Baylor College of Medicine and UCLA, focusing on pharmacokinetics and biochemistry of non-steroid inflammatory drugs, and cell cycle regulation. He has been regular reviewer or ad hoc reviewer for several medical journals, different funding agency and several journal Editorial Board members and senior Editors.

Vasiliki E. Kalodimou is Director of the Flow Cytometry-Research and Regenerative Medicine Department at IASO Maternity-Pediatric and Research Hospital in Athens, Greece. Before her current appointment, Kalodimou served as a haematology associate at General University Hospital of Heraklion, Crete, and as an instructor at both the General University Hospital of Heraklion and the Ipokratios Medical- Technical Institute of Athens. Kalodimou received her bachelor’s degree in Human Physiology and her master’s degree in Human Molecular Genetics from the Imperial College at the University of Medicine in London, UK. She completed her PhD at the University of Medicine in Athens, Greece, with an emphasis on stem cells and factors affecting their viability and absolute numbers.

Since 2006, Dr. Kalodimou has studied and working with stem cells from placenta, umbilical cord and adipose tissue, in every day practice and their applications in regenerative medicine and Flow Cytometry. Also is working in the area of human genetics & population genetics. In collaboration with the Hellenic Flow Cytometry Society, Kalodimou has developed quality control schemes for stem cell marker enumeration. The goal of this work is to find helpful new applications for flow cytometry, evaluate the risk factors for stem cell infusion, and improve the clarity and accessibility of measurements by flow cytometry. Her work quantifies and ranks all risks of flow cytometry enumeration to prevent and minimize the false-positive results from different cytometer uses. She is also working to establish combinations of monoclonal antibodies for mesenchymal and adipose tissue stem cell enumeration. In addition to collaboration with state universities and pharmaceutical companies on research projects, Kalodimou frequently publishes her findings. The Greek edition of the book was published in 2010 and has been well-received while in 2013 the English edition of the book was puplished by AABB Press USA. She is a member of two subsections of the AABB Cellular Therapies Section and also an AABB assessor.

Dr. Mahin Khatami immigrated to USA in 1969 after training in Chemistry (BS) and Science Education (MS) in Iran. She received her MA in Biochemistry from SUNY at Buffalo (1977) and Ph.D. in Molecular Biology from the University Of Pennsylvania (UPA, 1980). Her Postdoctoral framings were in physiology, protein chemistry and immunology at UVA, Fox Chase Cancer Center & UPenn. She became A Faculty of Medicine at Dept. Ophthalmology-UPA until 1992; and in collaboration with a team of scientists, under direction and support of John H Rockey, MD, Ph.D., she quickly earned her supervisory responsibilities on two major projects; cell/molecular biology of diabetic retinopathy/maculopathy and experimental models of acute and chronic infl ammatory diseases. As a junior Faculty, she was perhaps a most productive scientist in the country as she published 39 scientifi c articles and over 60 abstracts in conference proceedings in the fi rst decade of her academic career. Since 1998, at NCI/NIH, extension of her earlier discoveries on immunobiology of infl ammatory diseases became closely relevant to her duties as Program Director-HAS for developing concepts for molecular diagnosis ,prevention and therapy of cancer for large clinical Trials ( Prostate-Long-Colorectal- Ovarian) and designs of cohort clinical studies. Dr. Khatami has lectured internationally; served as scientifi c judge; consultant to pharmaceutical companies; research advisor; member of professional societies; editorial member ships & reviewer activities; symposia organizer; president of graduate women In Science, Washington Chapter. Before retiring in 2009, her position title was Assistant Director for Technology Program Development, Offi ce of Technology and Industrial Relations and Program Director-IMAT, Offi ce of Director, NCI/NIH. She is currently Book Editor on Infl ammatory Diseases.

Mary MehrnooshEshaghian-Wilner has over 26 years of research experience in various areas within the field of Computer Engineering. Additionally, she has worked in the area of patent law for several years. She has published numerous scientific papers, including two books, and has handled the prosecution and infringement analysis of many complex U.S. and international patents. Eshaghian-Wilner currently is a Professor of Engineering Practice at the Electrical Engineering-Systems Department at the University of Southern California (USC), and since 2004 has been an Adjunct Professor of Electrical Engineering at the University of California, Los Angeles (UCLA). Prior to joining UCLA, she was a tenured full Professor and Department Head at the Computer Engineering Department of Rochester Institute of Technology. Professor Eshaghian-Wilner received her B.S. Degree in Biomedical and Electrical Engineering (1985), M.S. Degree in Computer Engineering (1985), her Engineers degree in Electrical Engineering (1988), and her Ph.D. in Computer Engineering (1988), all from USC. She holds a J.D. Degree from the Northwestern California School of Law, and has graduated Cum Laude with an LL.M. Degree from the Thomas Jefferson School of Law. She is admitted to the State Bar of California and the Washington, D.C. Bar, and is registered as a Patent Attorney with the United States Patent and Trademark Office.

Computing Architectures and Interconnects: Bio-inspired and Nanoscale Computing, MEMS, Optical Interconnects, VLSI and Reconfigurable chips.Computing Networks and Algorithms: Heterogeneous/Cluster/Grid/Cloud Computing, Mapping and Scheduling paradigms/algorithms/tools. Biomedical Applications: Nanomedicine, Bioinformatics, Sequence Alignment, Image-Processing, Computer Vision. Technology Law: Technology Transfer, Intellectual Property, Patent Reform, Digital Rights, Cyber Law/Crimes, Internet Privacy

Dr. Xinghua (Victor) Pan earned his Ph.D. degree with Dr. CC Tan and Z Geng from the Institute of Genetics, Fudan University School of Life Science, Shanghai, China. His thesis research was on the genetic associations between HLA and SLE and myasthenia gravis. He also obtained his M.D. degree (equivalent) from the Southern Medical University (previously called First Military Medical University), Guangzhou, China. Then he got his postdoctoral training at the National Key Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) with Dr. Min WU, identifying a candidate tumor suppressor gene with a grant support from the China Postdoctoral Science Foundation. Beginning in December 1994, he served as Associate Professor in Genetics in the Department of Biology, Second Military Medical University, Shanghai, China, where he earned a grant from the National Natural Science Foundation of China (NSFC), with which he established nm23 transgenic mouse and elucidated its effect on hepatocarcinoma. In addition, he studied EBV BHRF1 on nasopharyngeal carcinoma, reconstructed the phylogenetic tree for MHC genes. In 1997, Dr. Pan joined Dr. Sherman Weissman’s laboratory as a Postdoctoral Fellow in the Department of Genetics, Yale University School of Medicine, and developed an approach (GADAV) for unconditionally globally scanning of DNA mutations. From 2000 to 2004, he worked with Dr. Roger Lasken for Molecular Staging Inc. as a Research Scientist in Genomics Section and then Enzymology Leader, substantially contributed to the development of a kit for whole-genome-amplification (WGA), REPLIg, which is currently used world-wide and regarded as one of the best WGA technologies.

Dr. Pan’s main interest is functional genomics, focusing on the development and application of functional genomics technologies for analysis of single cells and low quantity of cells. These approaches include whole DNA pool amplification, whole mRNA transcriptome amplification, CpG methylation pattern scanning, DNase hypersensitive and resistant sites profiling, and telomere size analysis. Combining these technologies with second generation sequencing and microfluidic platform, and collaborating with other research teams, his group explores the genomic and epigenomic mechanism for reprogramming and transdifferentiation of human induced pluripotent stem cells (iPS), differentiation of embryo stem cells (ESCs) and adult stem cells (ASC, including hematopoietic stem cells, mesenchymal stem cells), molecular regulation underlying sensory neurons, embryo development and carcinogenesis and translational medicine.

Dr. Olexander L. Kukharchuk was specialized as “medical practioner” at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). CMSc. (Candidate of Medical Science) defended on 1989 in the session of specialized academy council at Kaunaski Medical Institute (Lithuania). D.M.Sc (Doctor of Medical Science) defended 1996 in the session of specialized academic council at Odessa Governmental Medical University (Ukraine). Associate Professor obtained on 1996, Professor obtained on 2001. 1982-1991: Assistant, Department of Pathophysiology Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1991-1994: Senior Tutor, Normal Physiology with course of Pathophysiology at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). Head of the Central Research Laboratory and Senior Tutor of the Pathophysiology Department at Chernivtsi Government Medical Institute (Ukraine, Chernivtsi). 1994- 1995: Head of Central Research Laboratory, Associate Professor of the Normal Physiology Department at Bucovinian Government Medical Academy (Ukraine, Chernivtsi). 1995-1997: Director of the Centre for Scientific-Medical Investigation at Bucovinian Government Medical Academy (Ukraine, Chernivtsi). 1997- 2002: Head of the Normal Physiology Department at Bucovinian Government Medical University (Ukraine, Chernivtsi). 2002-2005: Research Director of the Centre for Embryonic Cells “EmCell”(Ukraine, Kiev). 2005-2006: Research Director of the Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry (Ukraine, Kiev). 2006-2010: Director of Coordination Centre for Transplantation of Organs, Tissues and Cells of the Ukraine Health Ministry; Chief Specialist of the Ukraine Health Ministry by specialization “Transplantology”; Research Director of Institute of Cell Therapy (Ukraine, Kiev); Director EmProCell Clinical Research Pvt. Ltd. (India, Mumbai)

Physician/Scientist, and faculty member of the Medical College of Cornell University and The New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his PhD Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewers of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer. Mutant BRCA1 and BRCA2 genes profiles in ovarian cancer. Proteomic profiling of metastatic genes of ovarian cancer. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer.

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China. He is also served as a principle investigator at the Hong Kong Cancer Institute. He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer. He has authored or co-authored ~120 papers and has written a number of books or book chapters. He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents. He was educated in China and United Kingdom and has MB and PhD degrees.

Apoptosis in cancer (hepatocellular carcinoma, lung cancer and thyroid cancer).

Margarita Glazova, received the Ph.D. (1997) fromSechenovInstitute of Evolutionary Physiology and Biochemistry, Russian Academy of Science and postdoctoral fellow of Adj. Professor P.Koskinen, Turku Centre for Biotechnology, University of Turku/ÅboAkademi, Finland (2001-2003). She was a Research Associate of Prof. A.K.Murashov, East Carolina University Brody School of Medicine, Department of Physiology, Greenville, NC, USA (2004-2006). She is a Senior Researcher at the Laboratory of Comparative Somnology and Neuroendocrinology, Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St.Petersburg, Russia. She has published more than 30 articles in peer-reviewed scientific journals